Background: Ongoing opioid analgesic use in patients suffering from chronic nonmalignant pain (CNMP) has been associated with the development of opioid misuse, abuse, addiction, and overdose. To prevent these adverse outcomes, it is important that family nurse practitioners (FNPs) implement recommended risk mitigation practices (RMPs) when treating CNMP patients with opioids. Methods: A national sample of 856 FNPs was invited to answer an online survey about their utilization of opioids and RMPs in treating CNMP. Results: One hundred sixty-eight FNPs responded (20% response rate), of whom 51.2% affirmed that they prescribe opioids for CNMP. Of the 86 FNPs who prescribe opioids, 66.7% said that less than 25% of their patients were receiving ongoing opioid therapy. The most frequently prescribed opioids were hydrocodone (77.9%) and oxycodone (58.1%). With respect to RMPs, 50 of the 86 opioid-prescribing FNPs (58.8%) reported using treatment contracts with their CNMP patients. Far fewer (20.9%) used formal screening tools to gauge the risk of opioid abuse and misuse. Most respondents (54.94%) reported using prescription monitoring programs, whereas only 33.0% reported using urine toxicology to monitor opioid use. Of the prescribing FNPs, 15.1% reported using abuse-deterrent opioid formulations. Age was found to be a correlate for prescribing opioids for CNMP, with those under 40 years of age less likely to use urine toxicology than those over 41 (45.2% vs. 4.2%; χ2(6) = 11.90, P = .06). Additionally, respondents who did not use treatment contracts reported significantly fewer years in practice (10.5 years, SD = 6.1) than those who did (13.6 years, SD = 1.54, df = 2.82, P = .02). Conclusions: Although RMPs are recommended for use in all CNMP patients receiving ongoing opioid therapy, FNPs do not consistently implement them. In the midst of the current opioid epidemic, FNPs must be vigilant about using appropriate opioid prescription practices.
NahinRL.Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16:769–780. doi: 10.1016/j.jpain.2015.05.002.
3.
ChouR, FanciulloGJ, FinePG, . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130. doi: 10.1016/j.jpain.2008.10.008.
4.
DaubresseM, ChangHY, YuY, . Ambulatory diagnosis and treatment of non-malignant pain in the United States, 2000–2010. Am J Emerg Med. 2013;51:870–878. doi: 10.1016/j.ajem.2014.01.015.
5.
GaskinDJ, RichardP. The economic costs of pain in the United States. J Pain. 2012;13:715–724. doi: 10.1016/j.jpain.2012.03.009.
SmithM, DaviesMA, StanoM, WhedonJM. Aging baby boomers and the rising cost of chronic back pain: secular trend analysis of longitudinal medical expenditures panel survey data for years 2000 to 2007. J Manipulative Physiol Ther. 2013;36:2–11. doi: 10.1016/j.jmpt.2012.12.001.
8.
LevyB, PaulozziL, MackKA, JonesCM. Trends in opioid analgesic-prescribing rates by specialty U.S., 2007–2012. Am J Prev Med.2015;49:409–413. doi: 10.1016/j.amepre.2015.02.020.
DunnKM, SaundersKW, RutterCM, . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med.2010;152:85–92. doi: 10.7326/0003-4819-152-2-201001190–00006.
12.
ChouR, TurnerJ, DevineE, . The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med.2015;162:276–286. doi: 10.7326/M14-2559.
13.
EdlundMJ, MartinBC, FanM, DevriesA, BradenJB, SullivanMD. Risks for opioid abuse and dependence among recipients of chronic pain opioid therapy: results from the TROUP study. Drug Alcohol Depend.2010;112:90–98. doi: 10.1016/j.drugalcdep.2010.05.017.
14.
ChangY, ComptonP. Management of chronic pain with chronic opioid therapy in patients with substance use disorders. Addict Sci Clin Pract.2013;8:1–11. doi: 10.1186/1940-0640-8-21.
Population Data and National Survey on Drug Use and Health (NSDUH). Substance Abuse and Mental Health Services Administration Web site. http://www.samhsa.gov/data/population-data-nsduh/reports. Updated2014. Accessed March 16, 2016.
21.
PaulozziL, BaldwinG, FranklinG, . CDC grand rounds: Prescription drug overdoses—a U.S. epidemic. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm. Published January 13, 2012. Accessed August 8, 2015.
22.
CalcaterraS, GlanzJ, BinswangerIA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009. Drug Alcohol Depend.2013;131:263–270. doi: 10.1016/j.drugalcdep.2012.11.018.
ChenJH, HumphreysK, ShahNH, LembkeA. Distribution of opioids by different types of medicare prescribers. JAMA Intern Med.2016;176:259–261. doi: 10.1001/jamainternmed.2015.6662.
OliverJ, CogginsC, ComptonP, . American society for pain management nursing position statement: pain management in patients with substance use disorders. Pain Manag Nurs.2012;13:169–183. doi: 10.1016/j.pmn.2012.07.001.
27.
DowellD, HaegerichT, ChouR. CDC Guidelines for Prescribing Opioids for Chronic Pain—United States, 2016. CDC Web site. http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm. Published March 15, 2016. Accessed April 5, 2015.
28.
ButlerSF, FernandezK, BenoitC, BudmanSH, JamisonRN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain.2008;9:360–372. doi: 10.1016/j.jpain.2007.11.014.
ReubenDB, AlvanzoAA, AshikagaT, . National institutes of health pathways to prevention workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med.2015;162:295–300. doi: 10.7326/M14-2775.
33.
HwangCS, TurnerLW, KruszewiskiSP, KolodnyA, AlexanderGC. Prescription drug abuse: a national survey of primary care physicians. JAMA Intern Med.2015;175:302–304. doi: 10.1001/jamainternmed.2014.6520.
34.
LewisM, HerndonCM, ChibnallJT. Patient aberrant drug taking behaviors in a large family medicine residency program: a retrospective review of screening practices, incidence, and predictors. J Opioid Manag.2014;10:169–175. doi: 10.5055/jom.2014.0205.
35.
StarrelsJL, BeckerWC, AlfordDP, KapoorA, WilliamsAR, TurnerBJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med.2010;152:712–720. doi: 10.7326/0003-4819-152-11-201006010–00004.
36.
TournebizeJ, GibajaV, MuszczakA, KahnJ. Are physicians safely prescribing opioids for chronic noncancer pain? A systematic review of current evidence. Pain Pract.2016;16:370–383. doi: 10.1111/papr.12289.
37.
ComptonP.Treating chronic pain with prescription opioids in the substance abuse: relapse prevention and management. J Addict Nurs.2011;22:39–45. doi: 10.3109/10884602.2010.545092.
38.
CheatleM, ComerD, WunschM, SkoufalosA, ReddyY. Treating pain in addicted patients: recommendations from an expert panel. Popul Health Manag.2014;17:79–89. doi: 10.1089/pop.2013.0041.
39.
ChouR, CrucianiRA, FiellinDA, . Methadone safety: a clinical practice guideline from the American pain society and college on problems of drug dependence, in collaboration with the heart rhythm society. J Pain.2014;15:321–337. doi: 10.1016/j.jpain.2014.01.494.
SekhonR, AminjavaheryN, DavisCNJ, RoswarskiMJ, RobinetteC. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at veterans affairs medical center (VAMC). Pain Med.2013;14:1548–1556. doi: 10.1111/pme.12164.
42.
ComptonP.The role of urine toxicology in chronic opioid analgesic therapy. Pain Manag Nurs.2007;8:166–172. http://www.ncbi.nlm.nih.gov/pubmed/18036504. Accessed August 8, 2015.
43.
ComptonP.Trust but verify. Pain Med.2014;15:1999–2000. doi: 10.1111/pme.12604_2.
44.
ReiflerLM, DrozD, BaileyEJ, . Do prescription monitoring programs impact state trends in opioid abuse/misuse?Pain Med.2012;13:434–442. 10.1111/j.1526-4637.2012.01327.x.
45.
MorganL, WeaverM, SayeedZ, OrrR. The use of prescription monitoring programs to reduce opioid diversion and improve patient safety. J Pain Palliat Care Pharmacother.2013;27:4–9. doi: 10.3109/15360288.2012.738288.
46.
RutkowL, TurnerL, LucasE, HwangC, AlexanderGC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff (Millwood).2015;34:484–492. doi: 10.1377/hlthaff.2014.1085.
MastropietroDJ, OmidianH. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm.2013;39:611–624. doi: 10.3109/03639045.2012.680468.
49.
CiceroTJ, EllisMS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxycontin. JAMA Psychiatry.2015;72:424–430. doi: 10.1001/jamapsychiatry.2014.3043.
50.
CiceroTJ, EllisMS, KasperZA.A tale of 2 ADFs: Differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.Pain.2016;157:1232–1238. doi: 10.1097/j.pain.0000000000000511.
51.
Department of Labor and Industries. Interim evaluation of the Washington state interagency guideline on opioid dosing for chronic noncancer pain. http;//www.agencymeddirectors.wa.gov/Files/AGReportFinal.pdf. Published August 31, 2009. Accessed April 11, 2016.
52.
PorucznikCA, JohnsonEM, RolfsRT, SauerBC. Opioid prescribing knowledge and practices: provider survey following promulgation of guidelines—Utah, 2011. J Opioid Manag.2013;9:217–224. doi: 10.5055/jom.2013.0162.
53.
McDonaldDC, CarlsonK, IzraelD. Geographic variation in opioid prescribing in the U.S. J Pain.2012;13:988–996. doi: 10.1016/j.jpain.2012.07.007.
54.
VolkowND, McLelllanTA, CottoJH, KarithanomM, WeissSRB. Characteristics of opioid prescriptions in 2009. JAMA.2011;305:1299–1301. doi: 10.1001/jama.2011.40.
55.
RingwaltC, GugelmannH, GarrettsonM, . Differential prescribing of opioid analgesics according to physician specialty for Medicaid patients with chronic noncancer pain diagnoses. Pain Res Manag.2014;19:179–185.
KellerCE, AshrafiounL, NeumannAM, Van KleinJ, FoxCH, BlondellRD. Practices, perceptions, and concerns of primary care physicians about opioid dependence associated with the treatment of chronic pain. Subst Abus.2012;33:103–113. doi: 10.1080/08897077.2011.630944.
LainieR, LydiaT, EleanorL, HwangC, AlexanderGC.Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access.Health Aff.2015;34:484–492. doi: 10.1377/hlthaff.2014.1085.
60.
JamisonRN, SheehanKA, ScanlanE, MatthewsM, RossEL. Beliefs and attitudes about opioid prescribing and chronic pain management: survey of primary care providers. J Opioid Manag.2014;10:375–382. doi 10.5055/jom.2014.0234.
61.
FontanaJS.The social and political forces affecting prescribing practices for chronic pain. J Prof Nurs.2008;24:30–35. doi: 10.1016/j.profnurs.2007.06.002.
62.
FranklinGM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American academy of neurology. Neurology.2014;83:1277–1284. doi: 10.1212/WNL.0000000000000839.
63.
McCrackenLM, BoichatC, EcclestonC. Training for general practitioners in opioid prescribing for chronic pain based on practice guidelines: a randomized pilot and feasibility trial. J Pain.2012;13:32–40. doi: 10.1016/j.jpain.2011.09.007.
64.
NuckolsT, AndersonL, PopescuI, . Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med.2014;160:38–47. doi: 10.7326/0003-4819-160-1-201401070-00732.
65.
HartrickCT, GatchelRJ, ConroyS. Identification and management of pain medication abuse and misuse: current state and future directions. Expert Rev Neurother.2012;12:601–610. doi: 10.1586/ern.12.34.
66.
ArgoffCE, KahanM, SellersEM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. J Opioid Manag.2014;10:119–134. doi: 10.5055/jom.2014.0201.
67.
HarihanJ, LambGC, NeunerJM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med.2007;22:485–490. doi: 10.1007/s11606-006-0084-1.
68.
KhalidL, LiebschutzJM, XuanZ, . Adherence to prescription opioid monitoring guidelines among residents and attending physicians in the primary care setting. Pain Med.2015;16:480–487. doi: 10.1111/pme.12602.
PerroneJ, DeRoosFJ, NelsonLS. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012. J Med Toxicol.2012;8:341–352. doi: 10.1007/s13181-012-0250-2.
71.
MorascoB, GritznerS, LewisL, OldhamR, TurkD, DobschaS. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain.2011;152:488–497. doi: 10.1016/j.pain.2010.10.009.
72.
LewisM, HerndonCM, ChibnallJT. Patient aberrant drug taking behaviors in a large family medicine residency program: a retrospective review of screening practices, incidence, and predictors. J Opioid Manag.2014;10:169–175. doi: 10.5055/jom.2014.0205.
73.
KatzNP, AdamsEH, ChilcoatH, . Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain.2007;23:648–660. doi: 10.1097/AJP.0b013e318125c5e8.
74.
BudmanSH, SerranoJMG, ButlerSF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J.2009;6:1. doi: 10.1186/1477-7517-6-8.
HenrySG, ChenM, MatthiasMS, BellRA, KravitzRL. Development of the chronic pain coding system (CPCS) for characterizing patient-clinician discussions about chronic pain and opioids. Pain Med.2016. pii: pnw005.
77.
TurnerJA, SaundersK, ShortreedSM, . Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results. J Gen Intern Med.2014;29:305–31. doi: 10.1007/s11606-013-2651-6.
78.
WestanmoA, MarshallP, JonesE, BurnsK, KrebsEE. Opioid dose reduction in a VA health care system—implementation of primary care population–level initiative. Pain Med.2015;16:1019–1026. doi: 10.1111/pme.12699.
